p.98 抽出テキスト

Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10. 1093/eurjpc/zwaa167 610. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA 2020;323:1934–44. https://doi.org/10.1001/jama. 2020.4249 611. Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J 2022;43:4980–90. https://doi.org/10.1093/eurheartj/ehac584 612. Pathak A, Poulter NR, Kavanagh M, Kreutz R, Burnier M. Improving the management of hypertension by tackling awareness, adherence, and clinical inertia: a symposium report. Am J Cardiovasc Drugs 2022;22:251–61. https://doi.org/10.1007/s40256-021- 00505-6 613. Sheppard JP, Lown M, Burt J, Temple E, Lowe R, Ashby H, et al. Generalizability of blood pressure lowering trials to older patients: cross-sectional analysis. J Am Geriatr Soc 2020;68:2508–15. https://doi.org/10.1111/jgs.16749 614. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events—meta-analyses of randomized trials. J Hypertens 2016;34:1451–63. https://doi. org/10.1097/hjh.0000000000000972 615. Jordan J, Tank J, Reuter H. Risk-benefit assessment of intense blood pressure lowering. Hypertension 2019;74:1302–4. https://doi.org/10.1161/hypertensionaha.119.13835 616. Rietz H, Pennlert J, Nordström P, Brunström M. Prevalence, time-trends and clinical characteristics of hypertension in young adults: nationwide cross-sectional study of 1.7 million Swedish 18-year-olds, 1969–2010. J Hypertens 2022;40:1231–8. https:// doi.org/10.1097/hjh.0000000000003141 617. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief 2020;364:1–8. 618. O’Neil A, Scovelle AJ, Milner AJ, Kavanagh A. Gender/sex as a social determinant of cardiovascular risk. Circulation 2018;137:854–64. https://doi.org/10.1161/ circulationaha.117.028595 619. Bruno RM, Pucci G, Rosticci M, Guarino L, Guglielmo C, Agabiti Rosei C, et al. Association between lifestyle and systemic arterial hypertension in young adults: a national, survey-based, cross-sectional study. High Blood Press Cardiovasc Prev 2016;23: 31–40. https://doi.org/10.1007/s40292-016-0135-6 620. Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, et al. Association of cardiovascular health metrics with risk of transition to hypertension in non-hypertensive young adults. Am J Hypertens 2022;35:858–66. https://doi.org/10.1093/ajh/hpac057 621. Haggart RC, Bartels CM, Smith MA, Johnson HM. Sociodemographics and hypertension control among young adults with incident hypertension: a multidisciplinary group practice observational study. J Hypertens 2018;36:2425–33. https://doi.org/10.1097/ hjh.0000000000001872 622. Liu J, Bu X, Wei L, Wang X, Lai L, Dong C, et al. Global burden of cardiovascular diseases attributable to hypertension in young adults from 1990 to 2019. J Hypertens 2021;39:2488–96. https://doi.org/10.1097/hjh.0000000000002958 623. Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension 2017;70:736–42. https://doi.org/10.1161/hypertensionaha.117.09801 624. Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol 2015;65:327–35. https://doi.org/10.1016/j.jacc.2014.10.060 625. Noilhan C, Barigou M, Bieler L, Amar J, Chamontin B, Bouhanick B, et al. Causes of secondary hypertension in the young population: a monocentric study. Ann Cardiol Angeiol (Paris) 2016;65:159–64. https://doi.org/10.1016/j.ancard.2016.04.016 626. Jones ESW, Esack I, Mangena P, Rayner BL. Hypertension in adolescents and young adults referred to a tertiary hypertension clinic in Cape Town, South Africa. Medicine (Baltimore) 2020;99:e23137. https://doi.org/10.1097/md.0000000000023137 627. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483–9. https://doi.org/10.1161/01.cir.94.3.483 628. Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 2003;67:19–24. https://doi. org/10.1016/s0010-7824(02)00429-8 629. The American College of Obstetricians and Gynecologists. ACOG practice bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2019;133:e128–50. https://doi.org/10.1097/aog.0000000000003072 630. Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 2018;25:1042–52. https://doi.org/10.1177/ 2047487318774847 631. Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception 2015;92:439–44. https://doi.org/10.1016/j.contraception.2015.07.014 632. Pappaccogli M, Di Monaco S, Warchoł-Celińska E, Lorthioir A, Amar L, Aparicio LS, et al. The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovasc Res 2021;117:950–9. https://doi.org/10.1093/cvr/cvaa102 633. Thompson P, Logan I, Tomson C, Sheerin N, Ellam T. Obesity, sex, race, and early onset hypertension: implications for a refined investigation strategy. Hypertension 2020; 76:859–65. https://doi.org/10.1161/hypertensionaha.120.15557 634. Saladini F, Fania C, Mos L, Mazzer A, Casiglia E, Palatini P. Office pulse pressure is a predictor of favorable outcome in young- to middle-aged subjects with stage 1 hypertension. Hypertension 2017;70:537–42. https://doi.org/10.1161/hypertensionaha.117. 09516 635. Hoeltzenbein M, Tissen-Diabaté T, Fietz AK, Zinke S, Kayser A, Meister R, et al. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors—treatment or hypertension related? An observational cohort study. Pregnancy Hypertens 2018;13:65–71. https://doi.org/10.1016/j.preghy.2018.04.022 636. Ahmed B, Tran DT, Zoega H, Kennedy SE, Jorm LR, Havard A. Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy. Pregnancy Hypertens 2018;14:156–61. https://doi.org/10.1016/j.preghy.2018.09.010 637. Cífková R, Johnson MR, Kahan T, Brguljan J, Williams B, Coca A, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother 2020;6: 384–93. https://doi.org/10.1093/ehjcvp/pvz082 638. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2022;27:148–69. https://doi.org/10.1016/j.preghy.2021.09.008 639. Kassebaum NJ, Barber RM, Bhutta ZA, Dandona L, Gething PW, Hay SI, et al. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016;388:1775–812. https://doi. org/10.1016/S0140-6736(16)31470-2 640. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol 2020;75:2323–34. https://doi.org/10.1016/j.jacc.2020.03.028 641. Heida KY, Franx A, van Rijn BB, Eijkemans MJC, Boer JMA, Verschuren MWM, et al. Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension 2015;66: 1116–22. https://doi.org/10.1161/hypertensionaha.115.06005 642. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens 2010;28:826–33. https://doi.org/10.1097/HJH.0b013e328335c29a 643. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24–43. https://doi. org/10.1161/hypertensionaha.117.10803 644. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens 2008;26:295–302. https://doi.org/10.1097/HJH.0b013e3282f1a953 645. Davis GK, Roberts LM, Mangos GJ, Brown MA. Comparisons of auscultatory hybrid and automated sphygmomanometers with mercury sphygmomanometry in hypertensive and normotensive pregnant women: parallel validation studies. J Hypertens 2015; 33:499–505; discussion 505–496. https://doi.org/10.1097/hjh.0000000000000420 646. Schmella MJ, Clifton RG, Althouse AD, Roberts JM. Uric acid determination in gestational hypertension: is it as effective a delineator of risk as proteinuria in high-risk women? Reprod Sci 2015;22:1212–9. https://doi.org/10.1177/1933719115572477 647. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613–22. https://doi.org/10.1056/NEJMoa1704559 648. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. BMJ 2008;336: 968–9. https://doi.org/10.1136/bmj.39540.657928.BE 649. Jeon HR, Jeong DH, Lee JY, Woo EY, Shin GT, Kim S-Y. sFlt-1/PlGF ratio as a predictive and prognostic marker for preeclampsia. J Obstet Gynaecol Res 2021;47:2318–23. https://doi.org/10.1111/jog.14815 650. Bateman BT, Bansil P, Hernandez-Diaz S, Mhyre JM, Callaghan WM, Kuklina EV. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol 2012;206:134.e1–8. https://doi.org/10.1016/j. ajog.2011.10.878 651. Zhou J, Azizan EAB, Cabrera CP, Fernandes-Rosa FL, Boulkroun S, Argentesi G, et al. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosteroneproducing adenomas presenting in puberty, pregnancy or menopause. Nat Genet 2021;53:1360–72. https://doi.org/10.1038/s41588-021-00906-y 652. Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G. Pheochromocytoma and pregnancy. Endocrinol Metab Clin North Am 2019;48:605–17. https://doi.org/10.1016/ j.ecl.2019.05.006 653. Bancos I, Atkinson E, Eng C, Young WF Jr, Neumann HPH, Yukina M, et al. Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective

ESC Guidelines                                                                                                                                                                                          4009

Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026